H.C. Wainwright maintains Buy on OKYO Pharma with $7 target
H.C. Wainwright reiterated its Buy rating on OKYO Pharma Ltd. (NASDAQ: OKYO) with a price target of $7.00, representing significant upside potential from the current trading price of $1.10. According ...
Business Wire6h
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...
Le Lézard4h
The American Diabetes Association Announces 2025 Pathway to Stop Diabetes Grant Recipients
Today, the American Diabetes Association® (ADA) announced the awardees of the 2025 Pathway to Stop Diabetes® (Pathway) grants.  This year's grants dedicate more than $6.1 million to support ...
Q4 2024 Vertex Pharmaceuticals Inc Earnings Call
Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...
Le Lézard10h
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment.Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...